4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $149 | $249 | $52 | $153 |
| Short-Term Investments | $276 | $39 | $161 | $95 |
| Receivables | $0 | $0 | $1 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $10 | $8 | $6 | $8 |
| Total Curr. Assets | $435 | $297 | $221 | $256 |
| Property Plant & Equip (Net) | $41 | $32 | $35 | $29 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $81 | $11 | $5 | $68 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $4 | $1 | $1 | $1 |
| Total NC Assets | $125 | $43 | $41 | $97 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $560 | $340 | $262 | $353 |
| Liabilities | – | – | – | – |
| Payables | $4 | $4 | $3 | $5 |
| Short-Term Debt | $6 | $3 | $3 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $1 | $3 |
| Other Curr. Liab. | $19 | $12 | $9 | $8 |
| Total Curr. Liab. | $29 | $19 | $16 | $16 |
| LT Debt | $19 | $12 | $13 | $15 |
| Deferred Rev, NC | $1 | $1 | $1 | $2 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $1 | $1 | $0 | $0 |
| Total NC Liab. | $21 | $13 | $15 | $18 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $25 | $15 | $13 | $16 |
| Total Liabilities | $50 | $32 | $31 | $34 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$576 | -$415 | -$314 | -$207 |
| AOCI | $0 | $0 | -$1 | -$0 |
| Other Equity | $1,087 | $723 | $547 | $527 |
| Total Equity | $511 | $308 | $231 | $319 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $560 | $340 | $262 | $353 |
| Net Debt | -$125 | -$234 | -$36 | -$137 |